Actively Recruiting
Phase II Study of SKB571 Treatment for Advanced Non-Small Cell Lung Cancer in Adults Aged 18 to 75
Led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Updated on 2026-05-12
295
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SKB571, an investigational drug, in a multicenter phase II study for patients with advanced non-small cell lung cancer. The study aims to assess the safety and early anti-tumor effects of SKB571 in this population. Eligible participants have locally advanced or metastatic disease and measurable tumors. Participants will receive SKB571 as a monotherapy injection every three weeks. Treatment continues until disease progression seen on scans, intolerable side effects, patient choice to stop, or other protocol-defined reasons. This study does not include placebo or other comparison treatments. During the study, patients will undergo regular monitoring including imaging scans to evaluate tumor response and safety assessments. Researchers will track adverse events and measure outcomes such as overall response rate, progression-free survival, duration of response, overall survival, and disease control rate up to 24 months. The study lasts until treatment stops or progression occurs, with close follow-up for up to two years.
CONDITIONS
Brief Title
A Phase II Study of SKB571 in Patients With Lung Cancer
Research Team
X
Xin Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here